SPION: Enhanced MR Imaging For Monitoring Alzheimer?s Plaque Formation And Microglial Activation In APP/PS-1 Transgenic Mouse Brain | 12470
Journal of Alzheimers Disease & Parkinsonism
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
We report MRI studies in APP/PS1 transgenic mice, which demonstrate the ability of our novel anti-amyloid precursor
protein (APP) conjugated superparamagnetic iron oxide nanoparticles (SPIONs) to penetrate the blood-brain barrier
to act as a contrast agent for plaque imaging. The conspicuity of the plaques increased from 5.1?0.5 to 8.3?0.2 when the plaque
contrast to noise ratio was compared in control AD mice with SPION-treated AD mice. The number of MRI-detected plaques
increased from 347 ? 45 in the control AD mice, to 668 ? 86 with SPION treatment. AD is associated with a microglia-dependent
neuro inflammation regulated by the pro-inflammatory transcription factor NF-?B. We therefore treated APP/PS1 mice for one
year with a low dose (100 ppm) of either of two trans-stilbene NF-?B inhibitors, resveratrol, or its synthetic analog, LD55. Both
trans-stilbenes lowered A? plaque density in the cortex, caudoputamen and hippocampus by 70-100%. Optical measurements
confirmed that resveratrol reduced average A? plaque density by 2.3 ? 0.4-fold. Ex vivo measurements of microglial activation by
Iba-1 immunofluorescence showed that resveratrol also reduced average microglial activation by 4.2-fold. The same concentration
of our novel trans-stilbene, LD55, produced a significantly larger (p<0.01) reduction in A? plaque density than resveratrol (3.1 ?
0.5-fold) as well as a 3.5-fold lowering of microglial activation. We conclude that SPION-enhanced MRI can be usefully applied
to studies of AD in Tg mice and that both resveratrol and LD55 are efficient at reducing A? plaque burden and concomitantly
reducing neuro inflammation in AD.
Laurel O. Sillerud completed his Ph.D. at the University of Minnesota, performed postdoctoral research at Yale University, directed the Biomedical
NMR Facility at Los Alamos National Laboratory, and currently is a Research Professor at the University of New Mexico, where he also directs the
MRI Core at the UNM Brain Center. He was elected as a fellow of the AAAS in 2013.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals